Literature DB >> 9564889

Detection of soluble Fas mRNA using in situ reverse transcription-polymerase chain reaction.

S H Lee1, S Y Kim, J Y Lee, M S Shin, S M Dong, E Y Na, W S Park, K M Kim, C S Kim, S H Kim, N J Yoo.   

Abstract

Fas protein (Fas) is known to induce cell death by apoptosis in susceptible cells. Alternative splicing of the Fas gene produces soluble Fas protein (sFas), which is considered to block the function of Fas. The serum level of sFas is elevated in patients with various malignancies in a manner reflective of disease stage and tumor burden, but the precise cellular origin of sFas in vivo has not yet been clarified. To identify the cells that synthesize sFas mRNA on histologic specimens, we applied in situ reverse transcription-polymerase chain reaction (in situ RT-PCR) in 11 cases of gastric adenocarcinoma/metastatic lymph node. Furthermore, we studied the distribution of Fas using immunohistochemistry and Fas mRNA using in situ RT-PCR. In all primary tumors and 10 of 11 metastatic tumors, tumor cells expressed both Fas- and sFas mRNA. Lymphocytes infiltrated in the tumor tissues and the lymph nodes also revealed both mRNA signals. A clear correlation between the tissue distribution for Fas and its mRNA was also observed. These observations demonstrated that solid tumors in vivo can synthesize sFas mRNA and suggest that tumor cells are responsible in part for elevated sFas in human malignancies. However, the additional expression of sFas mRNA in tissue lymphocytes indicates the complex regulatory mechanisms of Fas-mediated apoptosis pathway in tumor pathogenesis and host defense. We also demonstrated that in situ RT-PCR can be a suitable method for in situ detection of alternatively spliced mRNA.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9564889

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  7 in total

1.  Apoptosis during intramembranous ossification.

Authors:  Carla Palumbo; Marzia Ferretti; Anto De Pol
Journal:  J Anat       Date:  2003-12       Impact factor: 2.610

2.  Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma.

Authors:  M S Shin; W S Park; S Y Kim; H S Kim; S J Kang; K Y Song; J Y Park; S M Dong; J H Pi; R R Oh; J Y Lee; N J Yoo; S H Lee
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

3.  FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma.

Authors:  L Sehgal; R Mathur; F K Braun; J F Wise; Z Berkova; S Neelapu; L W Kwak; F Samaniego
Journal:  Leukemia       Date:  2014-04-03       Impact factor: 11.528

4.  Circulating and hepatic Fas expression in HCV-induced chronic liver disease and hepatocellular carcinoma.

Authors:  Azza E I El Bassiouny; Nora E I El-Bassiouni; Mona M F Nosseir; Mona M K Zoheiry; Eman G El-Ahwany; Faten Salah; Zeinab S O Omran; Raafat A Ibrahim
Journal:  Medscape J Med       Date:  2008-06-03

5.  Impaired expression of an organic cation transporter, IMPT1, in a knockout mouse model for kidney stone disease.

Authors:  Eleni G Tzortzaki; Min Yang; Dayna Glass; Li Deng; Andrew P Evan; Sharon B Bledsoe; Peter J Stambrook; Amrik Sahota; Jay A Tischfield
Journal:  Urol Res       Date:  2003-07-11

6.  hnRNP A1 contacts exon 5 to promote exon 6 inclusion of apoptotic Fas gene.

Authors:  Hyun kyung Oh; Eunkyung Lee; Ha Na Jang; Jaehoon Lee; Heegyum Moon; Zhi Sheng; Youngsoo Jun; Tiing Jen Loh; Sunghee Cho; Jianhua Zhou; Michael R Green; Xuexiu Zheng; Haihong Shen
Journal:  Apoptosis       Date:  2013-07       Impact factor: 4.677

7.  The role of fas/fas ligand system in the pathogenesis of liver cirrhosis and hepatocellular carcinoma.

Authors:  Olfat Hammam; Ola Mahmoud; Manal Zahran; Sohair Aly; Karim Hosny; Amira Helmy; Amgad Anas
Journal:  Hepat Mon       Date:  2012-11-03       Impact factor: 0.660

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.